Fundraising Fox
Comanche Biopharma
Concord, US · Founded 2020 · Delaware corporation · 33 employees on LinkedIn · 6 known investors
Find your way into Comanche Biopharma
Sign up to see every warm intro you have to Comanche Biopharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Comanche Biopharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women. It focuses on evidence-based therapies for life-threatening complications of pregnancy.
Founders & leadership
Comanche Biopharma was founded in 2020 by Mike Young and T Scott Johnson.
Board
Investors · 6
How we know: Atlas Venture's portfolio page · the company's own site · a partner's Signal profile · funding news · press coverage · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: GV (Google Ventures)'s portfolio page · the company's own site · a partner's Signal profile · funding news · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Broadview Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: F-Prime Capital's portfolio page · press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: a partner's Signal profile · funding news · press coverage · Not right? Tell us
Funding
SEC filings, press & company announcements$73.6M disclosed across 2 of 3 rounds · 2021–2025
- Undisclosed amountSeries BFeb 2025Source ↗
▶$37.5MraisedJan 2024 · 7 investors · PharmaceuticalsRule 506(b)
- Ann TaylorDirector
- Brendan Bulik-SullivanDirector
- Muzammil MansuriDirector
- Allison AugustExecutive Officer
- Paul AntinoriExecutive Officer
- Allyson FelixDirector
- David GrayzelDirector
- Thomas Scott JohnsonExecutive Officer, Director
- Scott GottliebDirector
- Ketan PatelDirector
- Michael YoungExecutive Officer
- Offering amount
- $75M
- Amount sold
- $37.5M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$36.1MraisedMay 2023 · 7 investors · PharmaceuticalsRule 506(b)
- Arthur LevinDirector
- Brendan Bulik-SullivanDirector
- Muzammil MansuriDirector
- Paul AntinoriExecutive Officer
- Allison AugustExecutive Officer
- Ann TaylorDirector
- Clive MeanwellDirector
- Allyson FelixDirector
- Ketan PatelDirector
- Michael YoungExecutive Officer
- Thomas Scott JohnsonExecutive Officer, Director
- Offering amount
- $36.1M
- Amount sold
- $36.1M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Comanche Biopharma.
In the news
Frequently asked questions
- What does Comanche Biopharma do?
- Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women. It focuses on evidence-based therapies for life-threatening complications of pregnancy.
- Who founded Comanche Biopharma?
- Comanche Biopharma was founded by Mike Young, T Scott Johnson in 2020.
- Who are Comanche Biopharma's investors?
- Comanche Biopharma's investors include Atlas Venture, GV (Google Ventures), Broadview Ventures, F-Prime Capital, Lilly Asia Ventures, New Enterprise Associates (NEA).
- How much funding has Comanche Biopharma raised?
- Comanche Biopharma has disclosed $73.6M raised across 2 of its 3 known rounds.
- Where is Comanche Biopharma headquartered?
- Comanche Biopharma is headquartered in Concord, US.